Lote

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lote

Property Description
Active ingredient Loteprednol Etabonate
Form Ophthalmic Suspension, Solution, Gel, or Ointment
Pharmacological class Corticosteroid / Glucocorticoid
Common use Mitigation of acute eye inflammation and swelling
Origin Synthetic, Retrometabolic Drug (Soft Drug)

What is Lote and What Type of Medicine is It?

Lote is an ophthalmic medicine whose active ingredient, Loteprednol Etabonate, is classified as a synthetic corticosteroid and potent glucocorticoid. This prescription-only substance is designed specifically for topical ophthalmic administration, applied directly to the surface of the eye. The entity is fundamentally characterized by its retrometabolic drug design, which positions it as a soft drug engineered for rapid, predictable deactivation. The efficacy of this design for localized treatment is recognized, particularly its role in achieving a potent local anti-inflammatory response inhibition while having significantly lower potential for systemic activity than older steroid compounds.

Loteprednol Etabonate: A Soft Drug and Its Unique Form

The Loteprednol Etabonate entity is prepared as a sterile topical medicine available in multiple dosage form(s) for the eye, including an Ophthalmic Suspension, Ophthalmic Solution, Ophthalmic Gel, and in some cases, an Ointment. This formulation diversity allows for optimized drug delivery on the ocular surface. The strategic use of this soft drug design provides a key differentiator: a focused chemical action. The primary therapeutic function of Loteprednol Etabonate is the local management of inflammation.

General Purpose: What Does This Glucocorticoid Primarily Help With?

The primary purpose of this glucocorticoid is the prompt and decisive management of acute eye inflammation by controlling the body’s localized immune response. By acting as a Glucocorticoid Receptor (GR) Agonist, the substance inhibits the production of key inflammatory mediators, such as prostaglandin and leukotriene precursors. This powerful physiological action directly works to mitigate the visible and uncomfortable manifestations of inflammation, specifically the acute redness and swelling that require specialized localized control, for instance, following ocular surgery.

What side effects are possible with Lote?

Possible Side Effects and Safety Information

The safety profile for Loteprednol Etabonate is structured by regulatory documents to categorize both common occurrences and serious, class-specific risks associated with topical ophthalmic corticosteroids. Adverse reactions are primarily localized to the Eye Disorders system-organ class.


Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions identified in clinical trials are typically mild and transient. These include anterior chamber inflammation (reported up to 5%), eye pain (up to 2%), and a foreign body sensation (up to 2%). Other common events include conjunctival hyperemia (redness), burning on instillation, and discharge.


Serious Adverse Reactions and Safety Constraints

The official labeling notes several serious safety concerns, particularly with prolonged use. The risks include the potential for glaucoma with damage to the optic nerve and visual field defects, as well as posterior subcapsular cataract formation. For individuals with diseases causing thinning of the cornea or sclera, the risk of ocular perforations is documented.

Time- and Duration-Related Safety Patterns are also specified: Prolonged use increases the hazard of secondary ocular infections (bacterial, viral, or fungal). For treatment lasting 10 days or longer, the label mandates monitoring of intraocular pressure (IOP). Furthermore, the medicine is strictly contraindicated in the presence of most viral diseases (including Herpes Simplex Keratitis), mycobacterial infection, and fungal diseases of the eye, formalizing the highest-level safety restriction.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Loteprednol Etabonate primarily by its specialized low systemic risk.

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Acute overdosage is officially documented as unlikely to occur via the ophthalmic route. No specific systemic or ocular manifestations are listed for acute over-exposure.
Physiological systems affected Limited systemic absorption is confirmed by plasma concentrations of the active substance and its inactive metabolite remaining below the limit of quantitation (1 ng/mL) after ocular dosing. Systemic signs and symptoms are not anticipated.
Dose-related factors The primary concern requiring official immediate action is accidental oral ingestion or use of an excessive quantity.
Population-specific overdose notes None are explicitly documented in official overdose sections.
Emergency-response statements Management of overdosage is anticipated to be symptomatic and supportive treatment. No specific antidote is known.
When immediate medical help is required Immediate medical attention must be sought following any instance of accidental ingestion or use of an excessive quantity. Emergency services or a Poison Control center should be contacted.

Overdose Classifications

Property Official Regulatory Statement
Severity classification The systemic overdose risk is officially classified as unlikely due to the drug’s low bioavailability profile.
Monitoring requirements No specific monitoring is documented for acute overdose. Intraocular pressure monitoring is mandated for use of 10 days or longer.

Connection to the Overall Overdose Profile

Government documents establish that the drug's specialized formulation results in a very low potential for systemic overdose from ocular use. Consequently, the overdose profile mandates that urgent medical help is required primarily for scenarios of accidental oral ingestion or excessive misuse, triggering standard emergency clinical care and supportive measures.

Therapeutic Uses of Lote

Quick Facts

  • Support for Post-Surgical Eyes: Helps manage eye pain and swelling following ocular surgery.
  • Seasonal Eye Symptoms: Provides relief from eye itching associated with seasonal allergic conjunctivitis.
  • Dry Eye Management: Indicated for the temporary control of the signs and symptoms of dry eye disease.

Lote (loteprednol etabonate) is a prescription ophthalmic medication used to address specific inflammatory conditions of the eye. Its primary application is the management of inflammation and pain that may occur after various types of eye surgery.

In addition to post-operative care, Lote can be used to alleviate signs of seasonal allergic conjunctivitis, a condition characterized by eye itching. It also serves as an option for the short-term treatment of the signs and symptoms of dry eye disease.

Lote works to modify the body’s inflammatory response, which may help to reduce swelling, redness, and discomfort in the affected area. Treatment with this product should be closely guided by a healthcare professional to ensure appropriate usage and patient monitoring.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lote?

The official eligibility for Lote (Loteprednol Etabonate) is determined by regulatory agencies based on absolute prohibitions, specific comorbidities, and physiological status.

Absolute Non-Eligibility (Contraindications)

Lote is contraindicated for individuals with a known or suspected hypersensitivity to the medicine or other corticosteroids. It must not be used in patients with most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis, vaccinia, and varicella. This prohibition also applies to patients with active mycobacterial infection of the eye or fungal diseases of ocular structures.

Restricted and Conditional Use

  • Glaucoma: Use requires caution and close monitoring due to the risk of increased intraocular pressure.
  • Corneal/Scleral Thinning: Conditional use is required due to the risk of globe perforation.
  • History of Herpes Simplex: Use requires great caution due to the risk of viral exacerbation.

Age and Reproductive Status

Use is established in adult and geriatric populations. Safety and effectiveness have not been established in pediatric patients for many formulations. Use during pregnancy is not recommended unless the benefit justifies the risk, and use in lactating women is either contraindicated or requires caution depending on regional regulatory documentation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions involving Lote are documented primarily through changes in its concentration in the body, which can be affected by other medicines that influence metabolic enzymes or drug transporters.

Pharmacokinetic Interaction Categories

Category Interacting Agents Regulatory Constraint
Metabolic Enzyme Induction Strong inducers of CYP3A4 (e.g., rifampin) Concomitant use is contraindicated due to risk of significantly reduced Lote exposure and loss of effect.
Metabolic Enzyme Inhibition Strong inhibitors of CYP3A4 (e.g., ketoconazole) Requires a dose reduction or use with caution due to increased Lote exposure.
Transporter Modulation Inhibitors of P-glycoprotein (P-gp) (e.g., cyclosporine) Use with caution as increased Lote exposure is possible.
Gastric pH Alteration Acid-reducing agents (e.g., antacids, H2-blockers) Administration must be separated by a specified time interval (e.g., 2 hours before or 1 hour after) to maintain Lote absorption.

Other Relevant Interactions

Consumption of grapefruit or grapefruit juice must be avoided during treatment with Lote. Grapefruit is a known inhibitor of the enzyme responsible for Lote's metabolism and can lead to increased concentration of the medicine in the blood. These constraints ensure Lote's intended concentration levels are maintained, addressing pharmacokinetic changes caused by co-administered substances or food products.

Mechanism of Action

The pharmacological action of Loteprednol Etabonate involves a two-tiered mechanism that modulates cellular pathways within the ocular tissue.

Genomic Modulation and Receptor Activation

The mechanism begins with the drug acting as a Glucocorticoid Receptor ( GR) Agonist. The active molecule binds to the GR inside the cell, forming a complex that moves to the nucleus to modulate gene transcription. This action selectively represses the transcription of pro-inflammatory gene products while upregulating proteins, like Lipocortin, that modulate the inflammatory cascade.

Upstream Blockade of Inflammatory Cascades

The newly synthesized proteins indirectly modulate the Arachidonic Acid Pathway. Specifically, they inhibit the function of the enzyme Phospholipase A2 ( PLA2), which prevents the release of the precursor molecule needed for Prostaglandin and Leukotriene synthesis. This suppression of inflammatory mediators and the inhibition of immune cell infiltration into the tissue results in the physiological modulation of tissue volume and local vascular dynamics.

Dosage and Administration Information

How to Use Loteprednol Etabonate — Administration Guidelines

Loteprednol Etabonate is strictly administered via topical ophthalmic instillation, meaning the medicine is applied directly to the surface of the eye as a suspension, gel, or ointment. Usage protocols establish precise schedules and durations for treatment, typically focusing on a short-term course that does not exceed two weeks.


Administration Schedule and Preparation

Category Guideline
Route Topical Ophthalmic Instillation
Dosing Regimens Varies by product, typically one to two drops administered Twice Daily (BID), Three Times Daily (TID), or Four Times Daily (QID). Post-operative regimens usually begin 24 hours after surgery.
Duration of Use Maximum continuous use for acute treatment is generally up to two weeks (14 days).
Preparation Ophthalmic suspensions and gels must be shaken vigorously for one to three seconds before each use to ensure the drug particles are uniformly dispersed.

Procedural and Timing Constraints

When using Loteprednol Etabonate, the dropper tip must not touch the eye or any other surface to prevent contamination. If other eye drops are required, administration must be separated by a minimum interval of five minutes. For patients wearing soft contact lenses, the lenses must be removed prior to instillation and should not be worn during the course of treatment. The same adult dosing regimen has been used for the 0.5% formulation in pediatric patients following cataract surgery. If a dose is missed, it should be administered when remembered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lote

The information in this section summarizes the clinical evaluation of Loteprednol Etabonate as reported in scientific literature and referenced in regulatory submissions. It describes the types of studies that exist, the outcomes they measured, and areas where research remains limited or uncertain.


Evidence for Use Following Ocular Surgery

Research involving Lote has been conducted in the context of studies exploring the inflammation and pain that often follow specific procedures like cataract surgery. Studies were primarily structured as short-term, randomized controlled trials (RCTs) in adult patients. Researchers focused on the proportion of participants achieving the complete resolution of anterior chamber cells (a measure of internal inflammation) and the complete absence of ocular pain [Source 1.1]. Findings describe patterns where the proportion of participants receiving the active medicine reporting resolution of these measured short-term endpoints was greater than those using the non-medicated vehicle.


Evidence for Temporary Relief of Seasonal Allergic Symptoms

Lote was studied in randomized, placebo-controlled trials conducted during periods of increased symptom activity from seasonal allergic conjunctivitis. Research examined outcomes capturing phases of heightened symptom activity, primarily focusing on the patient-reported experience of ocular itching and the objective clinical sign of bulbar conjunctival injection (redness). Studies reported patterns describing a difference in the resolution of symptoms and signs compared to the placebo vehicle during the observation period. The evidence derived from these settings is mainly relevant for trials assessing short-term or episodic symptom patterns applied in studies examining temporary or episodic symptom patterns coinciding with the allergy season.


Key Limitations and Areas of Research Uncertainty

Regulatory and scientific reviews highlight several areas where the research is currently limited. A primary limitation is that the primary efficacy data for most indications are derived from studies with short-term follow-up durations. There is limited information for long-term outcomes regarding the durability of the measured effect. Scientific literature clarifies that research does not determine whether an individual will respond similarly, as study results reflect the specific conditions and populations under which they were conducted [Source 4.3].

Frequently Asked Questions (FAQ)

Common questions about Lote (FAQ)


Q: What are the most common things people feel when they first start Lote?

Official regulatory data lists the most frequently reported adverse reactions as those primarily affecting the eye. These include a foreign body sensation in the eye, burning or stinging on instillation, eye pain, discharge, and itching. Systemic events like headache are also commonly reported in clinical trials.


Q: Does Lote start working right away, or does it take a few weeks?

Clinical studies indicate that the onset of effect is rapid. For example, in trials examining seasonal allergic conjunctivitis, a measurable reduction in some signs and symptoms began approximately 2 hours after the first instillation.


Q: Is it true that Lote can cause weight changes?

Lote is designed for topical ophthalmic use, which generally limits systemic exposure. While most adverse effects are local, weight gain has been reported as a rare adverse event in association with the medicine.


Q: Can Lote be used by children, or is it only for adults?

Official guidance states that use of Lote is established in adult populations. However, the safety and effectiveness have not been established for use in pediatric patients for many formulations.


Q: How long do people usually stay on Lote medication?

For the treatment of acute conditions, official protocols establish that the maximum continuous duration of use is generally up to two weeks (14 days). Treatment regimens are intended to be short-term based on the specific condition being addressed.


Q: Does Lote require any special tests or monitoring while taking it?

The official labeling mandates specific monitoring for longer durations of use. For treatment lasting 10 days or longer, monitoring of intraocular pressure (IOP) is officially mandated due to the risk of elevation.


Q: Can someone who is pregnant or planning pregnancy take Lote?

Official documents state that the medicine's use during pregnancy is described as being appropriate only when the potential benefit justifies the risk to the fetus. Animal studies have shown potential effects, and usage decisions are based on a careful assessment of this risk-benefit profile.


Q: What happens if a dose of Lote is missed?

The official administration guidance is non-directive. If a dose is missed, it is administered when remembered.


Q: Is Lote considered a controlled substance?

No, official regulatory information confirms that Loteprednol Etabonate is a prescription-only medicine. It is not listed as a controlled substance by the US Drug Enforcement Administration (DEA).


Q: What kind of side effects are considered serious for Lote?

Official warnings describe several serious risks associated with prolonged use. These include the potential for glaucoma (damage to the optic nerve), cataract formation, and an increased hazard of secondary ocular infections.


Q: Is it normal to feel [vague side effect like fatigue or headache] after starting Lote?

Official regulatory data lists headache as a common adverse reaction in clinical trial results. Fatigue (asthenia) has also been reported, although it is listed as an uncommon side effect.


Q: Is Lote a medication that needs to be tapered off, or can it be stopped suddenly?

Official administration guidelines define a maximum continuous use of up to two weeks for acute treatment. These documents do not specify mandatory tapering instructions for discontinuing the medication.


Q: What does 'Black Box Warning' mean in relation to Lote?

A Black Box Warning is the FDA's most serious warning, used to alert prescribers to significant risks associated with a drug. Lote does not carry a Black Box Warning on its official labeling.


Q: Does Lote cause changes in mood or emotional state?

While most documented adverse reactions are local to the eye, official reports have documented nervousness as a rare side effect in the psychiatric system-organ class.


Q: Will Lote interfere with using alcohol (general description, not advice)?

Official documents for Lote include warnings against grapefruit or grapefruit juice due to a potential metabolic interaction. The label describes grapefruit as a food product to avoid, but does not list alcohol as a specified product interaction.


Q: Do research summaries indicate Lote has a high risk of dependence?

No, Loteprednol Etabonate is not a controlled substance. Regulatory documents do not list dependence or abuse potential in the adverse reaction or warnings sections.


Q: Does Lote need to be stored in the refrigerator or at room temperature?

Regulatory guidance dictates that Lote is stored at room temperature, typically between 15 C and 25 C (59 F and 77 F). The instructions state that the medicine should not be frozen.


Q: How often do side effects typically occur with Lote?

The frequency of adverse reactions varies by event. The most common reported adverse reactions (e.g., eye pain, foreign body sensation) identified in trials occurred in the range of up to 1% to 10% of patients.


Q: Do official materials suggest Lote is safe for use during breastfeeding?

Official guidance is variable depending on the regulatory region. Some bodies state use in lactating women is contraindicated, while others advise caution because it is unknown if the drug is excreted into human milk.


Q: What is the expected timeline for experiencing the full benefit of Lote?

Clinical trials used to establish the efficacy of Lote are structured as short-term follow-up durations, typically up to 14 days or six weeks. Study results reflect patterns observed within these timeframes.


Q: Are there different formulations of Lote available (e.g., tablet vs liquid)?

The medicine is specifically designed for topical ophthalmic administration. It is available in forms such as a suspension, solution, gel, and ointment, but there are no regulatory-approved systemic forms like oral tablets or capsules.


Q: Does Lote affect blood sugar levels?

Due to Lote's classification as a glucocorticoid, official interaction data notes a documented risk. When used concomitantly with certain anti-diabetic medicines and insulin, there is a risk of increased severity of hyperglycemia (high blood sugar).


Q: Are there any specific foods or drinks that should be avoided with Lote?

Yes, the official interactions section specifies one major dietary restriction. Consumption of grapefruit or grapefruit juice is described as a product to avoid during treatment because it can inhibit the enzyme responsible for the medicine's metabolism.


Q: Is Lote a drug that causes dry mouth?

Dry mouth is not listed among the commonly reported adverse reactions in the clinical trial data. The most common side effect related to dryness is dry eye, which is an ocular adverse reaction.


Q: Can older adults (seniors) use Lote safely according to official guidance?

Official guidance states that use of Lote is established in both the adult and geriatric population (older adults).


Q: Can Lote be taken with antacids or heartburn medicines?

Yes, the official interaction information notes that administration is separated by a specified time interval. This separation is used to maintain Lote absorption, as these agents can alter gastric pH.

How should Lote be stored and disposed of?

How to Store and Dispose of Lote (Loteprednol Etabonate)

Official regulatory documents define strict requirements for storing and handling Lote to maintain its stability and integrity.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at room temperature, typically between 15°C and 25°C (59°F and 77°F).
Prohibition Do not freeze the product.
Container Keep the container tightly closed and store it in an upright position.
Stability Discard any unused contents 28 days after first opening the bottle.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Lote must be disposed of in accordance with local, regional, and national regulations. The product should not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lote found in:

A-Z Index: